irinotecan has been researched along with Experimental Mammary Neoplasms in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stringer, A; Sultani, M; Thorpe, D | 1 |
| Cheng, L; Feng, L; Gong, H; Gu, X; Liu, T; Liu, Z; Shi, X; Sun, B; Wang, C | 1 |
| Atyabi, F; Dinarvand, R; Ghahremani, MH; Khoshayand, MR; Montazeri, H; Ostad, SN; Rouhani, H; Sepehri, N; Tavassolian, F | 1 |
| Bateman, E; Keefe, D; Mayo, B; Stringer, A; Thorpe, D; Vanhoecke, B; Vanlancker, E | 1 |
| Chia, WT; Chung, MF; Lin, KJ; Liu, HY; Sung, HW | 1 |
| Cui, H; Lock, LL; Mao, W; Shen, Y; Sui, M; Sun, W; Tang, J; Wang, J; Xu, D | 1 |
| Aboody, KS; Annala, AJ; Garcia, E; Gilchrist, M; Glackin, CA; Gutova, M; Kim, SU; Metz, MZ; Najbauer, J; Polewski, MD; Zhao, D | 1 |
| Balasubramanian, BN; Fairchild, CR; Jang, GR; Long, B; Marathe, PH; Monticello, TM; Rose, WC; Wall, ME; Wani, MC | 1 |
| Kiselyov, A | 1 |
| Bowen, JM; Cummins, AG; Gibson, RJ; Keefe, DM; Tyskin, A | 1 |
| Andoh, T; Aogi, K; Fujiwara, Y; Hirabayashi, N; Kim, R; Kusano, T; Mizutani, A; Nishiyama, M; Okada, K; Sumiyoshi, H; Toge, T; Yamakido, M | 1 |
| Ara, G; Chan, V; Eder, JP; Northey, D; Rizvi, N; Teicher, BA; Wong, J; Wong, YW | 1 |
| Cvitkovic, E; Goldwasser, F; Raymond, E; Zeghari-Squalli, N | 1 |
1 review(s) available for irinotecan and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Mammary Neoplasms, Experimental; Methotrexate; Mice; Mucositis; Rats | 2015 |
12 other study(ies) available for irinotecan and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model.
Topics: Adenocarcinoma; Animals; Colon; Enterocytes; Female; Goblet Cells; Irinotecan; Jejunum; Mammary Neoplasms, Experimental; Mucin-2; Mucin-4; Mucositis; Rats, Inbred Strains | 2019 |
Drug delivery with PEGylated MoS2 nano-sheets for combined photothermal and chemotherapy of cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Chlorophyllides; Combined Modality Therapy; Disulfides; Doxorubicin; Drug Carriers; Female; HeLa Cells; Humans; Irinotecan; KB Cells; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Molybdenum; Nanostructures; Phototherapy; Pilot Projects; Polyethylene Glycols; Porphyrins; Radiation-Sensitizing Agents | 2014 |
SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Female; Humans; Irinotecan; Lactic Acid; Mammary Neoplasms, Experimental; Mice, Inbred BALB C; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Surface Properties; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
A pH-Responsive Carrier System that Generates NO Bubbles to Trigger Drug Release and Reverse P-Glycoprotein-Mediated Multidrug Resistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Drug Liberation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Hydrogen-Ion Concentration; Irinotecan; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Nude; Nitric Oxide | 2015 |
The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Female; Humans; Irinotecan; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Micelles | 2015 |
Human neural stem cell tropism to metastatic breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Delivery Systems; Female; Humans; Interleukin-6; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Invasiveness; Neural Stem Cells; Prodrugs; Rabbits; Xenograft Model Antitumor Assays | 2012 |
Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Gastrointestinal Tract; Humans; Irinotecan; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Nude; Ovarian Neoplasms; Prodrugs; Rats; Rats, Sprague-Dawley; Tumor Burden; Xenograft Model Antitumor Assays | 2006 |
Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Cancer mouse models and other techniques for improved prediction of efficacy.
Topics: Angiogenesis Inhibitors; Animals; Boronic Acids; Bortezomib; Camptothecin; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Forecasting; Gemcitabine; Green Fluorescent Proteins; Humans; Image Enhancement; Irinotecan; Luminescent Proteins; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Pyrazines; Red Fluorescent Protein; Technology, Pharmaceutical; Treatment Outcome | 2005 |
Irinotecan changes gene expression in the small intestine of the rat with breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 1; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Irinotecan; Jejunum; Mammary Neoplasms, Experimental; Mitogen-Activated Protein Kinase Kinases; Mucositis; Oligonucleotide Array Sequence Analysis; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation | 2007 |
Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Benzylisoquinolines; Biological Transport; Camptothecin; Cell Membrane; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Irinotecan; Mammary Neoplasms, Experimental; Mice; Tumor Cells, Cultured | 1997 |
Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; DNA, Neoplasm; Doxorubicin; Drug Interactions; Etoposide; Female; Irinotecan; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1998 |
Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Colonic Neoplasms; Cross-Linking Reagents; DNA Adducts; DNA Damage; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mammary Neoplasms, Experimental; Nucleic Acid Synthesis Inhibitors; Organoplatinum Compounds; Oxaliplatin; RNA, Neoplasm; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1999 |